Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship
NHS Guidelines on Self-Administering B12 Injections The NHS supports patient self-administration of B12 injections where clinically appropriate and following adequate training
The FDA has classified BPC-157 as a Category 2 bulk drug substance, i.e., its use raises significant safety concerns, and the available evidence is insufficient to support its safety
LOW VITAMIN B12 AND LIPID METABOLISM: EVIDENCE FROM PRE-CLINICAL AND CLINICAL STUDIES Increase in body mass index-standard deviation score was associated with a decrease in vitamin B12 levels
Does your cat have a chronic gastrointestinal problem
